CyclASol® – a preservative-free, clear cyclosporine A solution in Phase II for the treatment of moderate to severe DED (CYS-002).
What is special about CyclASol®?
Cyclosporine A has been proven to be the most successful API for the treatment of dry eye disease in the United States so far. In January 2017 Novaliq announced positive Phase 2 results evaluating CyclASol® in 207 patients with moderate to severe dry eye disease (DED). The reported data confirmed that CyclASol® had demonstrated a superior outcome and an early onset of action when compared head to head with Restasis™ (Allergan plc, USA).
What is the regulatory status of CyclASol®?
CyclASol® is in clinical development with New Drug Applications filings anticipated in USA, Japan and Europe.